Submission of Press Release that is being issued by the Company.

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Ltd, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition significantly expands Aurobindo's product offering in complex, non-opioid controlled substances and adds a U.S.-based manufacturing facility. The transaction, expected to close by end of June 2026, is anticipated to be immediately accretive to the Aurobindo Group's earnings per share. It is also projected to generate meaningful cost efficiencies, SG&A synergies, and enhance the company's differentiated pipeline for sustainable long-term growth.